Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years - Concepedia

Concepedia

Publication | Open Access

Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years

DOI Full Paper Access

82

Citations

23

References

2015

Year

Daniel J. Lovell, Nicolino Ruperto, Richard Mouy, Eliana Paz, Nadina Rubio‐Pérez, Clóvis A. Silva, Carlos Abud‐Mendoza, Rubén Burgos‐Vargas, V. Gerloni, José Melo‐Gomes,

Arthritis & Rheumatology

Abstract

Long-term abatacept treatment for up to 7 years was associated with consistent safety, sustained efficacy, and quality-of-life benefits in patients with JIA.

References

	Year	Citations

Page 1